UNSPSC 51124009: Lorcainide hydrochloride

This classification denotes an antiarrhythmic agent with the molecular formula C22H27ClN2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1T1S98ONM1, chemically known as benzeneacetamide, n-(4-chlorophenyl)-n-(1-(1-methylethyl)-4-piperidinyl)-, monohydrochloride but more generally known as lorcainide hydrochloride, which bears US NIH Compound Identifier 42883. European Medicines Agency schedules Lorcainide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02973MIG.

UNSPSC 51124009 Lorcainide hydrochloride, a Commodity code, encompasses antiarrhythmic pharmaceuticals and related injectable medications that state and local governments procure for emergency medical services, health systems, and pharmacy benefit programs. Recent solicitations show state and local buyers acquiring these drugs through direct purchase orders, cooperative purchasing agreements, and manufacturer-to-wholesaler distribution channels. The City of Tampa's Fire Rescue division, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the primary categories of issuing bodies—municipal emergency services departments, state health agencies, and multi-jurisdictional cooperative purchasing vehicles. Work under this code ranges from one-time sealed-bid procurements for specific medication line items to large-scale RFPs establishing standing contracts with multiple manufacturers and wholesalers serving statewide and multistate networks.

Activity centers in Texas, Minnesota, Florida, and Oregon, with the most recent volume driven by cooperative purchasing frameworks and state-level pharmacy benefit initiatives. The City of Tampa posted IFB No. 26P00188 on April 24, 2026, requesting Advanced Life Support Medications including epinephrine, labetalol, adenosine, and diltiazem for Tampa Fire Rescue, with a firm bid deadline of April 8, 2026 and an estimated contract value of $40,000.00 under a Small Local Business Enterprise sheltered market with a 5 percent bid discount cap. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, requiring manufacturers to supply through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with a two-year contract term and optional extensions through June 30, 2028. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, as a preliminary market intelligence phase seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling intent to formalize a subsequent RFP.